Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIGHT HOUSE: EPX-100 adjunctive therapy in Lennox-Gastaut syndrome
CTR20260854Phase 3Active
- Sponsor
- National Institute on Aging
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of clemizole in Lennox-Gastaut syndrome (LGS), sponsored by National Institute on Aging. Started Jun 2026; status: active.
02
Drugs
clemizole
03
Conditions
Lennox-Gastaut syndrome (LGS)
Beyond the preview
Go deeper on CTR20260854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260854.